Polaryx Therapeutics Common Stock EBIT

The latest EBIT for PLYX is $-4.7M as of March 2026. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Polaryx Therapeutics Common Stock's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, PLYX currently prints $-4.7M for EBIT, while the sector average sits near $23B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Polaryx Therapeutics Common Stock's growth, margins, and balance sheet.

A EBIT figure of $-4.7M for PLYX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting PLYX's EBIT ($-4.7M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Polaryx Therapeutics Common Stock's EBIT against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.